Connect with us

Cannabis News

Medical Marijuana ‘Significantly’ Decreases Use Of Opioids By Chronic Pain Patients, New Study Finds

Published

1 year ago

on

A new study shows that marijuana pain can be an effective replacement for the treatment of pain management.

Murdoch University researchers and research centers in Perth Pain Management Center to investigate how people who have been treating people with chronic cancer cancer pain.

Research published in Pain Management on Monday, “Cannabinoid co-prescriptions may be able to reduce the consumption prescribed for the chronic consumption of the pain kingdom.”

To assess the relationship between cannabis and opioids, the researchers followed two patients in a year: they were already in pain in the pain clinic and a Cannabis co-patient and another 53 patients, without Marijuanik, in a clinic.

Basically, median patient was taking about 40 mg opioids a day. After a year, 15 mg Delta-9 thc and 15 mg CBD median dose of 15 mg of CBD, the team “significantly” has reduced 2.7 mg of opioid doses per day. After a year, the opioid was only taking a median 42.3 mg per day.

“The introduction of cannabinoids can create useful reductions of opioid consumer settings in the real world, with additional benefits for disability and insomnia,” Authors of study celurbill. “However, this treatment is only subjected by a sub-group of patients.”

In the Kannabis treatment regiment between the cohort, “the opioid consumption has significantly reduced in 6 to 12 months.”

“Physical activity and sleep also improved. These findings indicate that medicinal cannabis can help patients reduce their opioid activity and improve their physical activity and sleep.

The findings are also consistent with the body of scientific literature, exploring the association between the use of cannabis and opioids.

For example, a study published this year earlier found in drug and alcohol review, among drug users who experience chronic pain every day The use of cannabis was related to greater probability of leaving opioids-Species among men.

Also found a study posted last year Legalization of medical cannabis seemed to significantly reduce the monetary payments of opioids What specializes in pain, authors “declining that in terms of Marijuana doctor, proves that they are available as a replacement.

Last studies also showed the decline of operating operations, legalized by marijuana for adults in jurisdictions. This study found a “Coherent negative relationship between legalization and aggression” has more significant effects on the states that were legalized before the cannon In opium crisis. The authors computed the legalization of recreation marijuana “that 3.5 per person per person is linked to reduction.”

“Our discoveries suggest that you can help recreating access to leisure marijuana to deal with the opioid epidemic,” said the report. “Previous research represents that marijuana (especially doctors) can reduce the prescriptions of opioids, and that we find that overdose can also reduce deaths.”

Another newly published report according to the use of Opioid opioid after the state Marijuana doctor legalization The availability of the legal cannabis was found that both patients with chronic pain reduced the opioid use and helped reduce deaths exceeded by prescription. Overall, the results of the study indicated that “Cannabis has a key role to play in pain management and reduce the use of opioids,” he said.

Another study published in 2023, linked to medical marijuana Minor level of pain and reduced dependence on opioids and other prescription medications. And other February, another published by the American Medical Association (Mother), found chronic pains that received medical marijuana for more than a month viewed important reductions in prescribed opioids.

About Three chronic pain patients reported using cannabis As a treatment option, 2023 mothers published by a report. Most of that group said they used cannabis as another substitute for pain medicines, including opioids.

Other research published that year found that People buy CBD legally significantly reduced opioid prescription feesIt has less recipe for 6.6 and 8.1 percent.

About prescription drugs Medicaid analyzed a 2022 research paper, while he found the legalization of marijuana for adult use “Reduced relevant” prescription drug use To treat multiple conditions.

2023 Report Medical Marijuana Medical Legalization Related Medical Payments reducing doctors-You have other data activities when they use legal access to the prescription drugs that patients use cannabis as an alternative.

Researchers in another study published last year examined Oregon opioid prescription and mortality rates to find it Marijuana retail access by reducing the prescriptions of oversized opioidsAlthough they saw a decline in the decline of death related to opioids.

Last research also indicates that cannabis can be an effective replacement of heels in terms of pain management.

Report published in BMJ magazine, such as marijuana and opioids for chronic painless pain and Canavies found “can be similarly effective and may have fewer interruptions than opioids” Provide potentially comparable relief with a lower chance of harmful effects.

Published special studies found more than half patients with chronic musculoskeletal pain, which was more effective than other analgesic medications cannabis, and 40% reported Reducing the use of other anes in the use of marijuana.

Marijuana is possible with the help of readers. If you are based on journalism to defend cannabis, consider the commitment to Patreon every month.

(Tagstotranslate) highlighted

Related Topics:
Continue Reading

Cannabis News

Fluent to sell New York license and operations

Published

1 month ago

on

July 30, 2026

By











Fluent has entered into a definitive agreement to sell Etain, LLC, the Company’s New York-based operating entity. The purchase agreement was signed on July 22, 2026. The transaction provides for the sale of Etain’s Registered Entity license, certain of the Company’s New York operating assets and related New York leases for cash, subject to customary purchase price adjustments.

The Company believes the Transaction advances its strategic objectives and expects the Transaction to comply with applicable regulatory requirements in connection with the Company’s previously announced plan of arrangement for Vireo Growth Inc. (the “Deal”) while providing for an orderly transition of the New York operations to an experienced operator committed to serving patients and consumers.

Completion of the free transaction is subject to closing conditions, including, among other customary conditions, approval of the change in ownership by the New York State Cannabis Control Board and the completion of all conditions to the completion of the Agreement.

For more information:
FLUENT Corp
getfluent.com/










Continue Reading

Cannabis News

Marijuana Has ‘Horrific Health Risks’ And No Medical Value, Former Trump Attorney General Claims

Published

1 month ago

on

July 30, 2026

By

A former US attorney general who served in President Donald Trump’s first term says marijuana poses “tremendous health risks,” has no medical value and should not be rescheduled under federal law.

“Marijuana redistricting would create a false impression that it is safe, reduce penalties for illegally selling the drug, and provide a large tax windfall to those who legally supply it,” William Barr wrote in a Wednesday op-ed for The Washington Post, Kevin Sabet, CEO of the prohibitionist organization Smart Approaches to Marijuana. “That would be a disaster.”

The opinion comes as the Trump administration moves forward with cannabis reregulation.

According to an order issued in April by US Attorney General Todd Blanche, Marijuana products regulated by a state medical cannabis license were immediately changed from Schedule I As did marijuana products approved by the Food and Drug Administration (FDA) under Schedule III of the Controlled Substances Act (CSA).

an administrator The hearing is looking at the broader rescheduling of marijuanawith The Drug Enforcement Administration (DEA) has been tasked with advocating for cannabis reform highlighting the testimony about the medical benefits of marijuana and its relative safety compared to other substances such as alcohol and opioids. It included appearances by a Food and Drug Administration (FDA) scientist and a doctor from New Hampshire. Medical marijuana provides relief to pain patients and can serve as an alternative to opioids.

But Sabet and Barr, who served as Trump’s attorney general from 2019-2020, argued that “the evidence presented at the hearing did not support the rescheduling of marijuana” and instead “confirmed what decades of data have shown: raw marijuana has no scientifically established medical value and is highly susceptible to abuse.”

After the parties to the hearing have filed termination rights, the DEA administrative law judge overseeing the proceedings will make a recommendation regarding rescheduling, and the agency administrator will make a final decision.

DEA Administrator Terrance Cole only organizations and individuals opposed to marijuana reform have been invited to the hearing as a designated participant – telling supporters that they do not meet the definition of “interested person” to participate because they have not been “affected or prejudiced by any rule or proposed rule that may be issued.”

—
It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.

Learn more about our marijuana bill tracking and become a Patreon supporter to gain access
—

The former attorney general’s new opinion says “the stakes couldn’t be higher”, arguing that “marijuana today is more dangerous than ever” and that it is “addictive”, throwing out a list of alleged harm to mental and physical health.

“These unhealthy effects are a predictable result of a powerful and addictive drug being normalized, commercialized and marketed as a medicine,” Barr and Sabet say. “It would be one thing if marijuana had medical value. But there is no credible evidence that marijuana is an effective treatment for any medical condition, despite the millions of dollars spent trying to prove otherwise.”

The Department of Health and Human Services (HHS) published a 252 analysis in 2023 that concluded that marijuana had accepted medical value and should be rescheduled.

The new opposition piece also says that “rescheduling would unlock enormous revenue for the corporate marijuana industry by bringing it into a category that has not been covered by a longstanding reduction in federal drug tax deductions,” referring to a law known as 280E, which repeals Sections I and II.

“This, in turn, would allow the industry to spend even more on advertising and marketing to young people,” Barr and Sabet. he wroteArguing that “those who would lose this dragon in society are laying the foundations for another Big Tobacco”.

The Sabet organization, SAM, is one of several parties Challenging the Marijuana Redistricting Process which have been upheld by a federal Court of Appeals. those separate parts State attorneys general have filed lawsuits against cannabis reform, Opponents of marijuana legalization and a a cannabis-based biopharmaceutical corporation.

SAM’s lawsuit was signed by attorneys at Torridon Law PLLC, where Barr is a partner.

The team announced in January that it was Hiring Barr’s firm to fight cannabis rescheduling After Trump signed an executive order directing officials to quickly complete the process.

During the first Trump administration, Barr was accused by a Justice Department official Directing improper anti-company investigations into multiple cannabis company mergers– Accounting for almost a third of the division’s cases in 2019.

Several Democratic members of Congress introduced a resolution calling for an investigation into Barr’s possible impeachment, saying “abused the power of his office” to improperly investigate marijuana businesses while engaging in other allegedly illegal conduct.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Continue Reading

Cannabis News

How much red light does cannabis really need?

Published

2 months ago

on

July 26, 2026

By

When growers pull out two LED fixtures side by side, the first number they usually discuss is percent red. This is an easy specification to fix. They are efficient at producing red photons and incredibly efficient at photosynthesis, and cannabis eats away at the flower. So more red must be better, right?

Not so simple. Red is an input to a spectrum, and the spectrum is an input to a room. There is no single spectrum that wins everywhere. An indoor room pushes hard, a greenhouse that soaks up sunlight, a temperamental cultivar, and aggressive yields call for something different. Knowing what each light strip actually does allows you to choose a tool that fits your grow instead of one that just has a big number on the sales page.

© JumpLights

Blue: structure
Blue (approximately 400-500 nm) gives shape to the plant. It maintains dense growth, strong stems, tight internodes and allows it to develop as desired. It also encourages stomatal opening, so the plant manages water and gas exchange better. Get blue and you’ve built a plant that can carry heavy flowers with no problem.

Green: access
Green was eliminated as the wavelength is “reflected” by plants. It turns out that it does a real job. Blue and red are absorbed above; the green goes deep into the fat and reaches the leaves that are never touched by the above photons. In a compact room, it’s the difference between plants photosynthesising from the top down and those that work only from the top. Green won’t replace your red or blue, but it does carry usable light where they can’t reach.

Red: engine
Red is the horse of the flower. It absorbs as efficiently as anything in the spectrum, and is responsible for most of the biomass you’re after. Redder generally means faster flower development, more weight and better efficiency per watt.

But red has a ceiling, and it’s tied to what you run. Push PPFD upwards with a heavy red spectrum and some cultivars begin to whiten at the top: the flower should be dense with pale, washed tips. Genetics, intensity, barrel temperature and your general environment all feed into it. If you’re using aggressive light levels, a lower red spectrum will buy you room before that becomes a problem, leaving you almost no photosynthetic punch to get it.

Far Red: More than Emerson
Far-red (700-750 nm) appears in more devices every year. It contributes little to photosynthesis on its own, but it moves plant morphology and works with red through the Emerson Enhancement Effect. Used properly, it helps to deepen the light, encourage uniformity of the canopy and encourage the response of the bloom. The key word is small. A touch of far red rounds out a spectrum; he’s not there to make a show.

Matching the red percentage with the room
Cannabis addresses the entire spectrum, not a line on a spec sheet. Reds cause flowers, but blues, greens and crimsons give the plant something it needs. Where you land in red refers to how you grow.

A lower red spectrum (30-40%) captures more blue and green, gives you better morphology, reduces the risk of photobleaching, and holds up when you’re running extreme PPFD. Moderate spectrum (40-55%) is the sweet spot in commercial greenhouses: strong photosynthetic efficiency, strong flowering, balanced growth. A high-red spectrum (70%+) makes the most sense in a greenhouse, where the sun is already giving you lots of blue and green and your supplemental light can cast effective red to fill the gap.

Where does the ETS MAX series fit in?
This is the thinking behind the JumpLights ETS MAX series. Instead of forcing a spectrum into each room, it rarely comes up because a greenhouse and a high PPFD indoor flower room are not the same problem.

  • ETS MAX 4C41% red: for indoor rooms operating at very high intensity, where photobleaching is a real risk. The wider, red bottom balance allows you to push the tops without overcooking them
  • ETS MAX 4A48% red: balanced internal spectrum that maintains high output while controlling bleaching.
  • ETS MAX 5B57% Red: A high-performance indoor option. Moderate red, marked with efficiency and flower at the same time, up to 3,450 μmol/s, with efficiency that holds the spectrum.
  • ETS MAX 7A76% red: built for the greenhouse. The sun already supplies blue and green, so this leans heavily on the complementary red, up to 3,900 μmol/s in the infrastructure most greenhouses already have in place.

Bottom line
Choosing an activity is not a competition for the highest red number. The winning spectrum is the one that matches your environment, your intensity, your genetics, and what you’re trying to produce. Combine spectrum, intensity, environmental control, light distribution and genetics, and you’ve got a lighting strategy. Keep a spec isolated and all you’ve got is a bright room.

The ETS MAX line was created around this idea: choose the spectrum of the room you actually have, indoor or greenhouse, and let the device work with your grow rather than against it.

For more information:
JumpLights
www.jumplights.com

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media